Endpoints NewsOriginal article
Otsuka reports long-term kidney data key to Voyxact's bid for full approval
Phase 3positiveVoyxactPositive
AI Analysis
Summary
Otsuka reported positive Phase 3 long-term data for Voyxact showing stabilization of kidney function, supporting the company's bid to convert the drug's accelerated approval to full FDA approval.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 study showed Voyxact stabilized kidney function
Importance:7/10
Sentiment:
0.75
accelerated approvalfull approvalkidney diseasePhase 3long-term data
Related Companies
Read the original article
Published by Endpoints News on July 2, 2026 2:50 PM